BIT Capital’s Tourmaline Bio TRML Stock Holding History

BIT Capital’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-747	Closed	-$55.5K	–	172
2022 Q2	$55.5K	Buy	+747	New	+$58.9K	0.01%	106

Other funds holding TRML

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIT Capital's TRML Position: Q3 2022 in Review

BIT Capital sold out of Tourmaline Bio (TRML) in Q3 2022, closing a stake of 747 shares — an estimated $55.5K sold.

BIT Capital first reported a position in TRML in Q2 2022 and held it in 1 quarter. The position peaked at $55.5K in Q2 2022. 56 funds tracked by Wall St. Rank hold TRML as of Q3 2022.

BIT Capital reported no remaining Tourmaline Bio position as of Q3 2022 after selling out during the quarter.
BIT Capital sold 747 Tourmaline Bio shares in Q3 2022, an estimated $55.5K.
BIT Capital first reported a position in Tourmaline Bio in Q2 2022 and held it in 1 quarter.
BIT Capital's Tourmaline Bio position peaked at $55.5K in Q2 2022.
56 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2022.

Based on BIT Capital's 13F filing for Q3 2022, filed 12 Feb 2025.